Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Warrant Money Planning

<< Previous

Bullboard Posts

Next >>

Comment by 90guppyon Jun 24, 2020 8:12pm

92 Views

Post# 31188450

RE:RE:RE:Warrant Money Planning

And another $2 million from the unexercised warrants of close to 20 million warrants before the new pp.

90guppy wrote: With regards to the funds coming from the pp and warrants, yes that's 10.2 Million, plus Canadian Govt money likely they will have 15 million dollars. More if you include the left over money before the pp. As for the approval, its likely done, silence from management is because of the intricacies of getting the agreement from Ben Gurion University and guys from Sheba Medical Center

bigbanktheory wrote: 90Guppy do you concur???